Warm brain-targeted butylphthalide nano-drug delivery system as well as preparation method and application thereof

Through the NBP@BPs@6sPCL-b-P(MEO2MA-co-OEGMA)-CRT nanodrug delivery system, the difficulty of butylphthalide drug is solved by combining black phosphorus quantum dots and temperature-sensitive amphiphilic nanopolymers with 808nm laser irradiation, the difficulty of butylphthalide drug is solved. The problem of crossing the blood-brain barrier has achieved effective brain aggregation of butylphthalide drugs and improved the therapeutic effect of Alzheimer's disease.

CN118924681APending Publication Date: 2024-11-12SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310521672.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing butylphthalide drugs are difficult to cross the blood-brain barrier, resulting in poor efficacy in treating neurological diseases such as Alzheimer's disease and lack effective brain-targeted delivery technology.

Method used

Using NBP@BPs@6sPCL-b-P(MEO2MA-co-OEGMA)-CRT nanodrug delivery system, the black phosphorus quantum dot and temperature-sensitive amphiphilic nanopolymer combined with 808nm laser irradiation is used to improve the brain targeting of the drug and Controlled release of drugs to enhance blood-brain barrier permeability.

Benefits of technology

The effective brain aggregation of butylphthalide drugs has been achieved, the therapeutic effect has been improved, the bioavailability and safety of the drugs have been enhanced, and the therapeutic effect of Alzheimer's disease has been significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_8
    Figure SMS_8
Patent Text Reader

Abstract

The invention provides a warm brain-targeted butylphthalide nano-drug delivery system and a preparation method and application thereof, the delivery system is NBP (at) BPs (at) 6sPCL-b-P (MEO2MA-co-OEGMA)-CRT, NBP is butylphthalide, BPs is black phosphorus quantum dots, 6sPCL-b-P (MEO2MA-co-OEGMA) is a thermosensitive amphiphilic nano-polymer, and CRT is a targeting molecule; the butylphthalide and the black phosphorus quantum dots are jointly wrapped in the 6sPCL-b-P (MEO2MA-co-OEGMA), the CRT is connected with the hydrophilic surface of the 6sPCL-b-P (MEO2MA-co-OEGMA), and the CRT is a simulated cyclic peptide of which the amino acid sequence is shown as follows: CRTIGPSVC; the butylphthalide nano-drug delivery system can be used for: (a) preparing a drug for treating and / or preventing Alzheimer's disease; (b) preparing an Alzheimer's disease diagnosis and / or prognosis evaluation reagent; the butylphthalide milk nano-drug delivery system has good biocompatibility, brain targeting property, controlled-release drug property and warm and photosensitive characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a warm brain-targeted butylphthalide nano-drug delivery system, a preparation method and an application thereof. Background Art

[0002] Butylphthalide (3-n-butylphathlide, NBP), chemical name 3-n-butylphthalide, also known as butylphthalide, is a new type of drug independently developed in my country. Its trade name is Enbipu. Its structure is shown in formula (I). Butylphthalide is a light yellow oily liquid, insoluble in water, soluble in methanol, ether and chloroform. The current marketed dosage forms are butylphthalide soft capsules and butylphthalide injection. Studies have shown that butylphthalide has the effects of anti-neuroinflammation, reducing Aβ deposition, regulating synaptic plasticity, inhibiting Tau protein hyperphosphorylation, etc. It has therapeutic effects on acute ischemic stroke, Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA) and other neurological diseases.

[0003]

[0004] Alzheimer's disease (AD) is an age-related neurodegenerative disease, which is mainly manifested by decreased learning and memory abilities. Currently, there are very limited drugs that can effectively treat AD. Butylphthalide is a drug for the prevention and treatment of AD. Due to its hydrophobicity and low permeability of the blood-brain barrier (BBB), even if butylphthalide is injected intravenously, it is difficult to direct the accumulation of butylphthalide at the lesion site, which seriously affects its therapeutic effect.

[0005] Therefore, there is still a need to study brain-targeted butylphthalide drug delivery technology, especially for the treatment of AD. Summary of the invention

[0006] The primary purpose of the present invention is to provide a warm brain-targeted butylphthalide nano drug delivery system. The nano drug delivery system provided by the present invention has good biocompatibility, brain targeting, drug controlled release, temperature sensitivity and photothermal properties, can promote butylphthalide to pass through the blood-brain barrier, and use 808nm laser light irradiation in a targeted manner to achieve drug aggregation in the brain; by means of butylphthalide's anti-neuroinflammation, anti-Aβ, anti-oxidative stress, anti-apoptosis, neuroprotection and other effects, the butylphthalide drug concentration in the brain is effectively increased through the nano drug delivery system to achieve brain-targeted treatment.

[0007] Another object of the present invention is to provide a method for preparing the above-mentioned warm brain-targeted butylphthalide nano-drug delivery system.

[0008] Another object of the present invention is to provide an application of the above-mentioned warm brain-targeted butylphthalide nano-drug delivery system.

[0009] The purpose of the present invention is achieved through the following solutions:

[0010] A warm brain-targeted butylphthalide nano-drug delivery system, characterized in that: the drug delivery system is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT, wherein NBP is butylphthalide, BPs is black phosphorus quantum dots, 6sPCL-bP(MEO2MA-co-OEGMA) is a thermosensitive amphiphilic nanopolymer, and CRT is a targeting molecule; the butylphthalide and black phosphorus quantum dots are co-encapsulated in the interior of 6sPCL-bP(MEO2MA-co-OEGMA), the CRT is connected to the hydrophilic surface of 6sPCL-bP(MEO2MA-co-OEGMA), and the CRT is a simulated cyclic peptide with the amino acid sequence as shown below: CRTIGPSVC, i.e., cysteine ​​(C)-arginine (R)-threonine (T)-isoleucine (I)-glycine (G)-proline (P)-serine (S)-valine (V)-cysteine ​​(C).

[0011] The average particle size of the nano drug delivery system is about 100-200 nm, preferably 120-180 nm.

[0012] The CRT is connected to the hydrophilic surface of 6sPCL-bP (MEO2MA-co-OEGMA), and preferably the CRT is connected to the hydrophilic surface of 6sPCL-bP (MEO2MA-co-OEGMA) through a covalent bond, effectively transporting the hydrophobic drug butylphthalide to the target site in the brain, thereby improving the therapeutic effect of the drug.

[0013] In the above delivery system, black phosphorus quantum dots (BPQDs, BPs for short) are zero-dimensional structure nanomaterials, which are good photothermal materials. They not only have high specific surface area, no biological toxicity, and good biocompatibility, but also have an absorption band that spans the ultraviolet to near-infrared region. They can quickly and effectively convert near-infrared light (e.g. 808nm) into thermal energy, significantly increase the permeability of the blood-brain barrier, and facilitate the role of butylphthalide. Black phosphorus quantum dots can be obtained by liquid phase ultrasonic etching, or purchased through commercial channels.

[0014] In the above delivery system, 6sPCL-bP (MEO2MA-co-OEGMA) is a water-soluble, non-biotoxic, thermosensitive amphiphilic nanopolymer, and its structure is shown in formula (II).

[0015]

[0016] Wherein, in formula (II),

[0017] R is C 10 H 16 O, structural formula is n is 8-16, preferably 10-14, and more preferably 12.

[0018] p is 40-56, preferably 44-52, more preferably 48.

[0019] q is 1-5, preferably 2-4, and more preferably 3.

[0020] MEO2MA is 2-methyl-2-acrylate-2-(2-methoxyethoxy)ethyl ester, the structural formula is It is polyMEO2MA, a thermosensitive polymer with an LCST of about 26°C; OEGMA is oligoethylene glycol methyl ether methacrylate with the structural formula It is poly-OEGMA, another thermosensitive polymer with an LCST of about 90°C; MEO2MA and OEGMA copolymerize to form P (MEO2MA-co-OEGMA) polymer, and its LCST can be adjusted by adjusting the number (p, q) of MEO2MA and OEGMA polymers.

[0021] The LCST (lower critical solution temperature) of the 6sPCL-bP (MEO2MA-co-OEGMA) is 40-50°C, preferably 42.3°C;

[0022] The present invention further provides a method for preparing the above-mentioned warm brain-targeted butylphthalide nano-drug delivery system, comprising the following steps:

[0023] S1, 6sPCL-bP(MEO2MA-co-OEGMA) was dissolved in solvent, water was added, and blank micelles were obtained after dialysis;

[0024] S2, dissolving butylphthalide in THF to obtain a butylphthalide solution; mixing the blank micelles obtained in step S1 with the butylphthalide solution and black phosphorus quantum dots, adding water, and dialyzing to obtain a solution of NBP@BPs@6sPCL-bP (MEO2MA-co-OEGMA) loaded with black phosphorus quantum dots and butylphthalide drug-loaded micelles;

[0025] S3. Add EDC and NHS to the solution obtained in step S2 in sequence, add CRT polypeptide after the reaction, dialyze, and freeze-dry to obtain the drug-loaded micelles NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT.

[0026] Wherein: EDC is 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; NHS is N-hydroxysuccinimide.

[0027] In step S1, the weight-to-volume ratio of 6sPCL-bP(MEO2MA-co-OEGMA) and THF is preferably (20-30 mg):2 mL; more preferably 20 mg:2 mL.

[0028] In step S1, the solvent is preferably an organic solvent, more preferably THF.

[0029] In step S1, water is preferably added under stirring, and more preferably water is added under stirring using a microinjector.

[0030] In step S1, the water is preferably deionized water.

[0031] In step S1, the rate of the micro-injector is preferably 2-3 mL / h, and the amount of water is preferably 5-7 mL; more preferably, the rate is 2.5 mL / h, and the amount of water is 5 mL.

[0032] In step S1, the dialysis time is preferably 24 to 30 hours, and more preferably 24 hours.

[0033] In step S1, the dialysis is preferably performed using a dialysis bag with a molecular weight cutoff of 8000 to 12000 Da, and more preferably a dialysis bag with a molecular weight cutoff of 10000 Da.

[0034] In step S2, water is preferably added under stirring, and more preferably water is added under stirring using a microinjector.

[0035] In step S2, the preferred rate of the micro-injector is preferably 2-3 mL / h, and the amount of water is preferably 5-7 mL; more preferably, the rate is 2.5 mL / h, and the amount of deionized water is 5 mL.

[0036] In step S2, the reaction conditions are preferably stirring for 12 to 15 hours and dialysis for 24 to 48 hours; more preferably stirring for 12 hours and dialysis for 24 hours.

[0037] In step S2, the dialysis is preferably carried out using a dialysis bag with a molecular weight cutoff of 15,000 to 45,000 Da; more preferably, a dialysis bag with a molecular weight cutoff of 30,000 Da is used.

[0038] In step S2, the dialysis time is preferably 20 to 30 hours, and more preferably 24 hours.

[0039] In step S3, the weight ratio of EDC to NHS is preferably 1:1; the use of EDC and NHS in a specific ratio can significantly improve the EDC coupling efficiency.

[0040] In step S3, the amount of the micelle solution is preferably 25-30 mL, with a concentration of 2-3 mg / mL; more preferably 25 mL, with a concentration of 2 mg / mL.

[0041] In step S3, the weight-to-volume ratio of the CRT polypeptide to the drug-loaded micelle solution is preferably 2-3 mg:25 ml; more preferably 2.5 mg:25 ml.

[0042] In step S3, the reaction time is preferably 2 to 4 hours, with water changed every 4 to 6 hours; more preferably, the reaction time is 2 hours, with water changed every 6 hours.

[0043] In step S3, the dialysis is preferably ice bath dialysis, preferably implemented by using a dialysis bag with a molecular weight cutoff of 100,000 to 200,000 Da; more preferably implemented by using a dialysis bag with a molecular weight cutoff of 100,000 Da.

[0044] In step S3, the ice bath dialysis time is preferably 20 to 30 hours, and more preferably 24 hours.

[0045] The thermosensitive amphiphilic nanopolymer 6sPCL-bP (MEO2MA-co-OEGMA) can be purchased through commercial channels, or can be prepared according to the method provided by the present invention.

[0046] In one embodiment of the present invention, a method for preparing 6sPCL-bP(MEO2MA-co-OEGMA) is provided.

[0047] A method for preparing a thermosensitive amphiphilic nanopolymer 6sPCL-bP (MEO2MA-co-OEGMA) comprises the following steps:

[0048] A. ε-CL, initiator dipentaerythritol and stannous octoate were mixed and stirred for reaction; the reactants were precipitated with methanol, filtered and dried to obtain the product 6sPCL;

[0049]

[0050] In the above formula, R and n are as defined above.

[0051] B. Dissolve the 6sPCL and 2-bromoisobutyryl bromide obtained in step A in chloroform respectively, add triethylamine to the chloroform solution of 6sPCL, stir and cool to -5°C to 5°C. Drop the dissolved 2-bromoisobutyryl bromide into the 6sPCL system and stir (free radical polymerization) for reaction. Extract with a mixture of chloroform and water, concentrate under reduced pressure, precipitate the concentrate in methanol, and dry. The obtained product is 6sPCL-Br;

[0052] The initiator is 6sPCL-Br, with a measured molecular weight of 8494 Da and the following structure:

[0053]

[0054] C. Add cuprous bromide, 6sPCL-Br obtained in step b, MEO2MA, OEGMA and THF to the reaction bottle in sequence; inject PMDETA into the system, perform polymerization reaction, cool the reactor to -5°C to 5°C, and terminate the reaction. Dilute the obtained crude product with THF to remove the copper salt catalyst; precipitate with n-hexane and dry; the obtained product is 6sPCL-bP (MEO2MA-co-OEGMA);

[0055] In the above preparation method: ε-CL is ε-caprolactone; THF is tetrahydrofuran; PMDETA is N,N,N',N,'N"-pentamethyldiethylenetriamine; and all liquid reagents used must be dehydrated with calcium hydride in advance.

[0056] The molecular weight of 6sPCL described in step A is preferably 7000-8000 Da, and more preferably 7801 Da.

[0057] The weight ratio of the ε-CL and the initiator dipentaerythritol in step A is (60-70):1; more preferably 68.5:1

[0058] The reaction conditions in step A are preferably under argon protection, the reaction temperature is 110-120° C., and the reaction time is 20-30 h; more preferably under argon protection, the temperature is 115° C., and the reaction time is 24 h.

[0059] The number of precipitations in step A is preferably 2 to 4 times, more preferably 3 times.

[0060] The weight ratio of 6sPCL to triethylamine in step B is 6-7:1, and more preferably 6.67:1.

[0061] The weight ratio of 6sPCL and 2-bromoisobutyryl bromide in step B is (4-5):1; more preferably 4.2:1.

[0062] The volume ratio of chloroform to water in the chloroform-water mixture in step B is preferably 1:1.

[0063] The molecular weight of 6sPCL-Br described in step B is 8000-9000 Da, and more preferably the molecular weight is 8494 Da.

[0064] The reaction conditions described in step B are preferably under argon protection for 20 to 30 hours; more preferably 24 hours.

[0065] The titration time in step B is preferably 25 to 45 min; more preferably 30 min.

[0066] The number of extractions in step B is preferably 2 to 4 times, and the number of precipitations is 1 to 3 times; more preferably, the extractions are performed 3 times and the precipitations are performed 2 times.

[0067] The molecular weight of 6sPCL-bP (MEO2MA-co-OEGMA) described in step C is preferably 18000-20000 Da, and more preferably 18490 Da.

[0068] The weight ratio of cuprous bromide, 6sPCL-Br, MEO2MA and OEGMA in step C is (0.052-0.060):1.0:(3.0-3.2):(0.65-0.70), preferably 0.056:1.0:3.117:0.684; the volume of the organic solvent tetrahydrofuran used is preferably 10-20 mL; more preferably 15 mL.

[0069] The weight ratio of PMDETA to 6sPCL in step C is preferably 0.050-0.055:1; more preferably 0.054:1.

[0070] The polymerization reaction conditions described in step C are preferably a temperature of 50-60° C. and a time of 4-6 h; more preferably a temperature of 50-55° C. and a time of 4 h.

[0071] Another object of the present invention is to provide the use of the above-mentioned warm brain-targeted butylphthalide nano-drug delivery system for:

[0072] (a) preparing a medicament for treating and / or preventing Alzheimer's disease;

[0073] (b) Preparing a diagnostic and / or prognostic evaluation reagent for Alzheimer's disease.

[0074] The present invention further provides a warm brain-targeted nano drug delivery system, wherein the drug delivery system is BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT, wherein BPs, 6sPCL-bP(MEO2MA-co-OEGMA), and CRT are as described above. The drug delivery system detects amyloid deposition by magnetic resonance imaging, so that it has the performance of diagnosing AD and evaluating drug efficacy. The present invention further provides the use of the warm brain-targeted nano drug delivery system in the preparation of Alzheimer's disease diagnosis and / or prognosis evaluation reagents.

[0075] The present invention examines the biological toxicity of nanoparticles to cells by CCK8 detection method. The results show that the survival rate of HT22 cells in the nano drug delivery system solution reaches more than 80%, indicating that the prepared nano drug delivery system has good biocompatibility and safety.

[0076] The present invention uses APPswe / PS1dE9 double transgenic mice (AD or Tg mice for short) as an animal model for studying AD. The selected 11-12 month old mice have a large amount of Aβ deposition in the cerebral cortex and hippocampus, and C57BL / 6J mice (WT mice for short) are used as a negative control group. The present invention uses in vivo fluorescence imaging to detect the brain targeting of the nano drug delivery system. After administration through the tail vein, it shows that the mice treated with targeted nano micelles have stronger fluorescence signals in their brains, indicating that the CRT-modified nano micelles have the ability to penetrate the BBB and can deliver drugs to the brain in a targeted manner.

[0077] By adopting the above technology, compared with the prior art, the advantages and features of the present invention are as follows:

[0078] (1) The hydrophobic polymer PCL is introduced into the nano drug delivery system, which can couple the hydrophobic drugs to achieve the drug encapsulation effect. In order to ensure that the fat-soluble drug carrier is not recognized by the mononuclear macrophages in the body during transportation, this deficiency is overcome by grafting, copolymerization and other methods, and the hydrophilic P (MEO2MA-co-OEGMA) polymer is introduced to form a temperature-sensitive star-shaped block copolymer 6sPCL-bP (MEO2MA-co-OEGMA) for the delivery of butylphthalide.

[0079] (2) The black phosphorus quantum dots selected in the present invention enable the prepared drug-loaded nanoparticles to have both temperature-sensitive and photothermal properties. Under the irradiation of an 808nm near-infrared laser, as the temperature rises to the lower critical transition temperature (LCST) of the polymer, the hydrophilic shell that originally played a protective role gradually precipitates from the aqueous solution due to a phase transition. After the "core-shell" structure of the micelles is destroyed, butylphthalide is discharged naturally, thereby realizing the intelligent release of the drug.

[0080] (3) Encapsulating butylphthalide inside a drug carrier can effectively solve the shortcoming of its short half-life, improve the water solubility of the drug and its stability in systemic circulation, and prolong the circulation time of the drug in the body by delaying the release of the drug, thereby improving the bioavailability of the drug.

[0081] (4) The CRT-modified nanodrug delivery system is enriched in the brain in a short period of time, which is beneficial for shortening the drug's peripheral circulation time, avoiding systemic adverse reactions caused by the drug, and achieving targeted drug treatment.

[0082] (5) The NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT provided by the present invention has good biocompatibility, brain targeting, controlled drug release, thermal and photosensitivity properties. Description of the drawings:

[0083] Figure 1 The 6sPCL, 6sPCL-Br and 6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 1 1 HNMR spectrum.

[0084] Figure 2 Infrared spectra of 6sPCL, 6sPCL-Br and 6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 1.

[0085] Figure 3 The particle size distribution diagrams of the two nano micelles prepared in Example 2; wherein A is the particle size distribution diagram of the prepared blank micelles, and B is the particle size distribution diagram of the prepared black phosphorus quantum dot-butylphthalide drug-loaded micelles.

[0086] Figure 4 UV-visible spectra of blank micelles (micelles) prepared in Example 2, butylphthalide (NBP) and drug-loaded micelles (NBP-micelles) prepared in Example 3, and standard curves of absorbance.

[0087] Figure 5 Gel permeation chromatograms of 6sPCL, 6sPCL-Br and 6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 1.

[0088] Figure 6 The photothermal performance test diagram of the drug-loaded micelles prepared in Example 3; wherein, A is the time-temperature curve diagram of the prepared micelle material under different concentration conditions, B is the time-temperature curve diagram of the prepared micelle material under different power conditions, C is the photothermal efficiency test diagram of the prepared micelles, and D is the infrared thermal imaging diagram of the prepared micelles under 808nm laser irradiation.

[0089] Figure 7 This is the temperature variation curve of the aqueous solution permeability of 6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 1.

[0090] Figure 8 This is the standard curve of UV-visible absorbance of NBP at different concentrations.

[0091] Fig. 9 The drug release curves of the drug-loaded micelles prepared in Example 3 in PBS solutions at 25°C, 37°C and 45°C.

[0092] Fig.10 This is the result of CCK-8 method detection of the effect of different concentrations of 6sPCL-bP (MEO2MA-co-OEGMA) on HT22 cells.

[0093] Fig.11 This is the result of observing the uptake of targeted (CRT-micelles) and non-targeted (micelles) nanomicelles by HT22 cells using fluorescence microscopy.

[0094] Fig.12 Figure 1 is the endocytosis diagram of HT22 cells to targeted (CRT-micelles) and non-targeted (micelles) nano-micelles; Figure A is the flow cytometric diagram of endocytosis of HT22 cells to targeted and non-targeted nano-micelles detected by flow cytometry; Figure B is a further endocytosis quantitative diagram.

[0095] Fig.13 This is a diagram showing the distribution results of ICG-labeled non-targeted and targeted nano-drug carriers in the brain;

[0096] A is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA) (non-targeted),

[0097] B is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT (targeted).

[0098] C is a comparison of the average fluorescence intensity of non-targeted and targeted nanodrug carriers in the brain. DETAILED DESCRIPTION

[0099] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0100] The experimental methods in the following examples are all conventional methods unless otherwise specified; the experimental materials used are all purchased from conventional biochemical reagent manufacturers unless otherwise specified.

[0101] Example 1: Preparation of thermosensitive amphoteric polymer 6sPCL-bP (MEO2MA-co-OEGMA)

[0102] Step A: Preparation of 6sPCL

[0103] Take 41.09g ε-CL (360mmol), 0.6g initiator dipentaerythritol (2.36mmol), and 200μL Sn(Oct)2 and add them to the reaction bottle. Under argon protection, stir and react in an oil bath at 115℃ for 24h. Dissolve the crude product obtained by the reaction in dichloromethane and precipitate it three times with ice methanol as a precipitant. The reaction is filtered and dried to obtain 24.6g of the product 6sPCL.

[0104] Step B: Preparation of 6sPCL-Br

[0105] Take 10g 6sPCL (containing 3.46mmol hydroxyl) and dissolve it in 50mL dry chloroform. At room temperature and under argon protection, add 1.5g triethylamine (14.82mmol) to the above solution and cool it to 0°C. 2-Bromoisobutyryl bromide (2.382g, 10.36mmol) dissolved in 20mL dry chloroform is added dropwise to the 6sPCL system within 30min. Under argon protection, stir the reaction at room temperature for 24h. Filter, extract the filtrate three times with a mixture of chloroform and water in a volume ratio of 1:1, collect the organic phase, concentrate, precipitate the concentrate in ice methanol twice, dry, and the resulting product is 6sPCL-Br, weighing 5.7g.

[0106] Step C: Preparation of 6sPCL-bP(MEO2MA-co-OEGMA)

[0107] 56 mg of cuprous bromide (0.39 mmol), 1.0 g of 6sPCL-Br initiator (containing 0.33 mmol of C-Br group), 3.117 g of MEO2MA (16.56 mmol), 0.684 g of OEGMA (1.44 mmol) and 15 mL of THF were added to the reaction bottle, and the system was protected by argon. 54 mg of PMDETA (0.26 mmol) was added to the reaction system under argon protection. After stirring the polymerization reaction at 50 ° C for 4 hours, the temperature was quickly cooled to 0 ° C to terminate the reaction. The crude product was diluted with THF, and the copper salt catalyst was removed in a neutral alumina column; precipitated with ice n-hexane and dried; the product obtained was 6sPCL-bP (MEO2MA-co-OEGMA), weighing 1.8 g.

[0108] Figure 1 for 6sPCL, 6sPCL-Br and 6sPCL-bP(MEO2MA-co-OEGMA)1 H NMR spectrum: (1)

[0109] 6sPCL 1 H NMR spectrum: The proton shift of -CH2O- in pentaerythritol is at 3.65 ppm (d), and the signal peaks at 1.38 (a), 1.69 (b) and 2.31 (c) ppm correspond to the -CH2- protons in the PCL skeleton. (2) 6sPCL-Br 1 HNMR spectrum: The initiator 6sPCL-Br is obtained by bromination reaction of 6sPCL. Its molecular weight is slightly higher than that of 6sPCL, and a proton signal peak of -CH3 appears at 1.95ppm(e); (3) 6sPCL-bP(MEO2MA-co-OEGMA) 1 HNMR spectrum: The thermosensitive block copolymer 6sPCL-bP (MEO2MA-co-OEGMA) was prepared by ATRP reaction of 6sPCL-Br, MEO2MA and OEGMA. The signal peaks appearing at 0.90 (f) and 1.82 (g)-1.92 (h) ppm correspond to the -CCH3- and -CH2- protons in the methacrylate backbone, proving the successful synthesis of the thermosensitive amphoteric polymer.

[0110] Figure 2 The infrared spectra of 6sPCL, 6sPCL-Br and 6sPCL-bP (MEO2MA-co-OEGMA) are shown in the figure. -1 is the stretching vibration peak of hydroxyl group, 1720cm -1 It is the stretching vibration peak of the ester bond of the PCL fragment. There is an additional peak of 1047 cm in 6sPCL-bP (MEO2MA-co-OEGMA). -1 The peak at , which is the stretching vibration peak of the COC chemical bond, indicates that the MEO2MA-co-OEGMA copolymer is formed. These results show that the 6sPCL-bP (MEO2MA-co-OEGMA) polymer was successfully prepared.

[0111] Figure 5 Gel permeation chromatograms of the prepared 6sPCL, 6sPCL-Br and 6sPCL-bP (MEO2MA-co-OEGMA): the average molecular weight of 6sPCL was 7801Da; 6sPCL-Br was 8494Da; 6sPCL-bP (MEO2MA-co-OEGMA) was 18490Da, proving that 6sPCL-bP (MEO2MA-co-OEGMA) has been successfully prepared.

[0112] Example 2: Preparation of butylphthalide nano-micelles

[0113] Step S1: Preparation of blank micelles

[0114] Take 20 mg of 6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 1 and dissolve it in 2 mL of THF. Use a microinjector to dropwise add it into 5 mL of deionized water at a rate of 2.5 mL / h under stirring; then place the mixed solution in a dialysis bag (molecular weight cutoff of 10000 Da) and dialyze it in 1000 mL of deionized water (pH = 7.4) for 24 h; change the water regularly 6 times to obtain blank micelles.

[0115] Step S2: Preparation of loaded black phosphorus quantum dots and / or butylphthalide micelles

[0116] Step S2-1: Preparation of black phosphorus quantum dots and butylphthalide loaded micelles

[0117] Dissolve butylphthalide (5 mg) in THF (2 ml) to obtain a butylphthalide solution; mix the blank micelles obtained in step S1, the butylphthalide solution, and 2 mg of black phosphorus quantum dots, and add dropwise to 5 mL of deionized water at a rate of 2.5 mL / h using a microinjector under stirring. After stirring for 12 hours, dialyze in an ice bath (molecular weight cutoff of 30,000 Da) for 24 hours to obtain black phosphorus quantum dot-loaded butylphthalide drug-loaded micelles NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA) solution.

[0118] Step S2-2: Preparation of micelles loaded with butylphthalide

[0119] Dissolve butylphthalide (5 mg) in THF (2 ml) to obtain a butylphthalide solution; mix the blank micelles obtained in step S1 and the butylphthalide solution, add dropwise into 5 mL of deionized water at a rate of 2.5 mL / h using a microinjector under stirring, stir for 12 h, and dialyze in an ice bath (molecular weight cutoff of 30,000 Da) for 24 h to obtain a micelle NBP@6sPCL-bP (MEO2MA-co-OEGMA) solution loaded with butylphthalide.

[0120] Step S2-3: Preparation of black phosphorus quantum dot-loaded micelles

[0121] The blank micelles obtained in step S1 and 2 mg of black phosphorus quantum dots were mixed, and added dropwise to 5 mL of deionized water at a rate of 2.5 mL / h using a microinjector under stirring. After stirring for 12 h, the mixture was dialyzed in an ice bath (molecular weight cutoff of 30,000 Da) for 24 h to obtain a black phosphorus quantum dot-loaded butylphthalide drug-loaded micelle BPs@6sPCL-bP (MEO2MA-co-OEGMA) solution.

[0122] An appropriate amount of sample was dissolved and diluted into a 1 mg / mL solution, 1 mL of blank micelles and black phosphorus quantum dot-loaded butylphthalide micelles were added to the sample pool, and the particle size was measured using a dynamic light scattering laser nanoparticle size analyzer at a measurement temperature of 25°C.

[0123] Figure 3 The particle size distribution diagrams of the two prepared nano-micelles are shown in Figure 1, where A is the particle size distribution diagram of the prepared blank micelles, and B is the particle size distribution diagram of the black phosphorus quantum dot butylphthalide loaded micelles. Figure 3 It can be seen that the micelle particle size distribution is uniform, the blank micelle particle size is concentrated around 127nm, the PDI is 0.02, and the particle size of the micelle after drug loading is slightly increased to about 156nm, and the PDI is 0.05.

[0124] Example 3: Preparation of targeted butylphthalide-loaded micelle freeze-dried powder NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT

[0125] S3-1: Take 25 mL (2 mg / mL) of the black phosphorus quantum dot-loaded butylphthalide drug-loaded micelles (NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)) solution in Example 2, add 20 mg EDC, activate the micelles for 10 min, then add 20 mg NHS and react for 2 h. Add 2.5 mg CRT polypeptide and react overnight. Use a 100,000 Da dialysis bag to dialyze in distilled water in an ice bath for 24 h to remove free CRT polypeptide, and change the water every 6 h. Freeze-dry the micelle aqueous solution to obtain 45 mg of targeted drug-loaded micelle powder NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT.

[0126] S3-2: Take 25 mL (2 mg / mL) of the loaded black phosphorus quantum dot micelle solution (BPs@6sPCL-bP(MEO2MA-co-OEGMA)) in Example 2, add 20 mg EDC, activate the micelles for 10 min, then add 20 mg NHS and react for 2 h. Add 2.5 mg CRT peptide and react overnight. Use a 100,000 Da dialysis bag to dialyze in distilled water in an ice bath for 24 h to remove free CRT peptide, and change the water every 6 h. Freeze-dry the micelle aqueous solution to obtain 42 mg of targeted micelle powder BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT

[0127] Example 4: Release behavior test of targeted butylphthalide-loaded micelles NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT

[0128] Take the NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT drug-loaded micelles prepared in Example 3; the release behavior of NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT at different temperatures in vitro was studied by measuring the content of NBP in the dialysate soaked with the drug.

[0129] The specific operation is as follows: 2mL NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT copolymer micelle solution is sealed in a dialysis bag (retention molecule is 1000Da), the dialysis bag is placed in a 15mL centrifuge tube, 2mL PBS (0.1M, pH 7.4) buffer solution is added to the centrifuge tube for drug release experiment, and the shaking speed is 150rpm. The drug release experiment is carried out at 25℃, 37℃ and 45℃ respectively. 1mL of dialysate is taken out with a pipette for testing at regular intervals. In order to keep the total volume of the solution of the release system unchanged, 1mL of fresh PBS buffer solution is immediately added to it. After 72h of drug release, the release amount of the drug at different temperatures is measured.

[0130] Fig. 9 Drug release curves of NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT micelles at different temperatures. When the temperature is 25°C, the copolymer micelles exist in a stable "core-shell" structure. The hydrophobic interaction between the drug and the inner core allows most of the oil-soluble drug NBP to exist stably inside the micelles to prevent drug leakage. When the temperature is 37°C, which is the in vivo environment, the "core-shell" structure of the micelles is destroyed, and the drug molecules are released to achieve the purpose of sustained release. When the temperature is 45°C, which is higher than the LCST of the thermosensitive copolymer, the hydrophilic outer shell that originally played a protective role gradually precipitates from the aqueous solution due to phase transition and adsorbs on the surface of the hydrophobic inner core. The "core-shell" structure of the micelles is destroyed. During the phase transition process, the water molecules inside the micelles will also be squeezed out as the hydrophilic outer shell shrinks and collapses. At the same time as the water molecules are expelled, some drug molecules will also be expelled, resulting in the release amount and release rate of the thermosensitive polymer drug-loaded micelles at 45°C being significantly higher than those at 25°C.

[0131] Example 5: Determination of drug loading of butylphthalide loaded micelles

[0132] Take 2mg NBP and 20mg 6sPCL-bP (MEO2MA-co-OEGMA) and dissolve them in 2mL THF. After stirring at room temperature for 1.5h, add them dropwise into 15mL deionized water and continue stirring for 2h. Then transfer the solution to a dialysis bag with a molecular weight cutoff of 3500Da and dialyze it in 600mL deionized water for 24h. Take the solution outside the dialysis bag after dialysis and measure the ultraviolet absorbance A at the selected wavelength. The NBP content obtained is the drug content (w') not encapsulated in the micelles, and the encapsulated drug content is w = 2mg-w', and then the drug loading capacity of the block copolymer micelles is calculated.

[0133] Figure 8 The standard curve of UV-visible absorbance of NBP at different concentrations. Figure 8 , and the drug loading rate was 10.6%.

[0134] Example 6: Spectrophotometric test of butylphthalide loaded micelles

[0135] The blank micelles prepared in Example 2, NBP, and the drug-loaded micelles NBP@6sPCL-bP (MEO2MA-co-OEGMA) prepared in Example 2 were uniformly dispersed in ultrapure water to prepare a solution with a concentration of 1 mg / mL, placed in a clean UV dish, and measured with a UV-visible spectrophotometer at room temperature, recording the spectrum in the range of 400-800 nm.

[0136] The results are as follows Figure 4 As shown. Figure 4 It can be seen that the pure drug NBP (butylphthalide) has an obvious absorption peak at 228nm, while the blank micelles (micelles) do not have any ultraviolet absorption peak at 200-600nm. The drug-loaded micelles (NBP-micelles) have an absorption peak at 228nm, proving that the preparation of the drug-loaded micelles is successful.

[0137] Example 7: Determination of LCST of Thermosensitive Amphiphilic Nanopolymer 6sPCL-bP (MEO2MA-co-OEGMA)

[0138] The lower critical transition temperature (LCST) of the thermosensitive polymer 6sPCL-bP (MEO2MA-co-OEGMA) was determined by turbidity. The transmittance of the thermosensitive copolymer micelle solution (1 mg / mL) at different temperatures was measured by UV-vis spectrometer. The wavelength used in this experiment was 500 nm. The temperature of the sample cell was controlled by a circulating water bath, and the temperature range used was 25-55°C. A curve was drawn with transmittance versus temperature, and the temperature at which the transmittance was 50% was defined as the LCST of the thermosensitive block polymer.

[0139] The results are as follows Figure 7 As shown in Figure 2, the LCST of the thermosensitive polymer 6sPCL-bP (MEO2MA-co-OEGMA) is 42.3 °C.

[0140] Example 8: Cytotoxicity test of thermosensitive amphiphilic nanopolymer 6sPCL-bP (MEO2MA-co-OEGMA)

[0141] The cytotoxicity of the nanoparticles was examined by co-culturing HT22 cells (commercially available) with the thermosensitive amphiphilic nanopolymer 6sPCL-bP (MEO2MA-co-OEGMA) and calculating the cell survival rate.

[0142] HT22 cells in logarithmic growth phase and good growth condition were selected for washing, digestion, centrifugation and cell counting. The cells were inoculated in a 96-well plate at a density of 5000 cells / well and then cultured in an incubator at 37°C, 5% CO2 and saturated humidity. After overnight adherence, the original culture medium was removed and replaced with a culture medium containing different concentrations of thermosensitive amphiphilic nanopolymers. The concentration of the selected material was set to 10-1000μg / mL, with 3 parallel wells for each concentration. Then cultured in an incubator for 24h. After culture, the cells were washed once with PBS and 100μL of fresh culture medium (containing 10% CCK-8) was added to each well. After incubation in an incubator for a period of time, the absorbance at a wavelength of 450nm was detected and recorded with an enzyme marker, and the cell survival rate was calculated by the absorbance.

[0143] Fig.10 The effects of different concentrations of 6sPCL-bP (MEO2MA-co-OEGMA) on HT22 cells were detected by CCK-8. The results showed that different concentrations of 6sPCL-bP (MEO2MA-co-OEGMA) nanoparticles had no obvious toxic effects on HT22 cells, and the cell survival rate was above 80%.

[0144] The CCK-8 kit is used to quickly and sensitively detect cell proliferation and cytotoxicity. The working principle is: in the presence of an electron coupling reagent, WST-8 (chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonylbenzene)-2H-tetrazole monosodium salt) can be reduced by dehydrogenase in the mitochondria to generate a highly water-soluble orange-yellow formazan product (formazan), the color depth of which is proportional to cell proliferation and inversely proportional to cytotoxicity. For the same cells, the color depth and cell number are linearly related. Using an enzyme reader to measure the OD value at a wavelength of 450nm can indirectly reflect the number of living cells.

[0145] Example 9: Test of HT22 cells for uptake of NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT

[0146] HT22 cells (commercially available) in logarithmic growth phase and in good growth condition were selected for washing, digestion, centrifugation, and cell counting. 4 HT22 cells were plated in 24-well plates and adhered overnight in a 37°C humidified incubator (5% CO2). Targeted (NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT) and non-targeted (NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)) nanoparticles were added to complete culture medium. Incubate with cells at 37°C for 6 hours, wash with PBS solution to remove free materials, fix cells with 4% paraformaldehyde, and wash three times with PBS. Add 1μLDAPI to each dish to stain the cell nucleus for 15 minutes, then wash the cells three times with PBS, and add 1mL PBS to each dish to maintain the normal morphology of the cells. Observe the cells and take pictures using a fluorescence microscope. At the same time, another batch of cells were incubated for 0.5, 2, 4 and 6 hours, and then the culture plate was placed in the incubator for another day. The cells were washed with PBS and digested with trypsin. After centrifugation, the supernatant was discarded and 200 μL of binding buffer was added to resuspend the cells. 5 μL of Annexin V-PE and 5 μL of 7-AAD were added for staining for 15 min. The cells were washed with PBS for 3 times and finally resuspended with 200 μL of PBS. The cells were detected by flow cytometry. The experiment was repeated three times for each drug and the results were statistically analyzed using the mean fluorescence intensity (MF) method.

[0147] Fig.11 The uptake of targeted and non-targeted nanodrug micelles by HT22 cells.

[0148] Fig.11 Fluorescence microscopy was used to detect the internalization process of targeted and non-targeted nanodrug micelles in HT22 mouse hippocampal neuronal cells. After incubation of non-targeted (micelles) and targeted (CRT-micelles) cells for 6 hours, the red fluorescence signal of ICG emitted by the targeted (CRT-micelles) group was significantly stronger than that of the non-targeted (micelles) group, indicating that the targeted (CRT-micelles) group was internalized by HT22 cells to a large extent.

[0149] Fig.12Figure 1 is a graph showing the endocytosis of HT22 cells to targeted and non-targeted nanomicelles; Figure A is a flow cytometric graph showing the endocytosis of HT22 cells to targeted and non-targeted nanomicelles detected by flow cytometry; Figure B is a further quantitative graph showing endocytosis.

[0150] Fig.12 Flow cytometry was used to detect the internalization process of targeted and non-targeted nanodrug micelles in HT22 mouse hippocampal neuronal cells; the results showed that the uptake of targeted nanodrug carriers (NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT; CRT-micelles) by HT22 cells was significantly increased, which means that the micelles prepared by the present invention have a suitable particle size and can be taken up by cells and enter the cytoplasm.

[0151] Fig.12 The targeting ability of HT22 cells was analyzed by flow cytometry to quantify the green fluorescence intensity in the cells. Under the same conditions, the fluorescence intensity of cells treated with micelles without targeting modification was used as a control. At different time points, the fluorescence intensity of the targeted micelle group was higher than that of the micelle group. As time went on, the fluorescence intensity in both groups of cells increased, but the fluorescence intensity of the targeted micelle group was still higher than that of the micelle, indicating that CRT can significantly enhance the cellular endocytosis efficiency of the nanosystem.

[0152] Example 10: Testing of the distribution of butylphthalide-loaded micelles in the brain

[0153] NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA) and NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT were mixed with ICG fluorescent molecules and incubated on a shaker at room temperature. After the incubation, the ICG fluorescent molecules that did not react with the nano-micelles were filtered out. The NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA) and NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT labeled with ICG fluorescent molecules were injected into AD mice through the tail vein (100 μL, concentration of 1 mg / mL). After the mice were anesthetized with tribromoethanol at 0h, 1h, 6h, 12h, 24h, and 48h, the distribution of nano-micelles in the brain was observed by fluorescence imaging using a living imaging system (excitation wavelength 704nm, emission wavelength 735nm). Note that the hair on the head should be removed to avoid affecting the imaging effect. The LivingImage software system was used for image processing.

[0154] Fig.13The distribution of ICG-labeled non-targeted and targeted nanodrug micelles in the brain, where A is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA) (non-targeted), B is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT (targeted), and C is a comparison of the average fluorescence intensity of non-targeted and targeted nanodrug carriers in the brain; the results show that the targeted nanomicelles modified with CRT are obviously aggregated in the brain.

[0155] Example 11: Intelligent release characteristics test of butylphthalide loaded micelles

[0156] In order to confirm that the drug-loaded micelles prepared in Example 3 have intelligent release characteristics, photothermal performance tests were performed.

[0157] First, the effect of concentration on the photothermal effect of the material was tested: drug-loaded micelles were dispersed in water to prepare solutions of different concentrations (0, 37.5, 75, and 150 μg / mL). At room temperature, 1 mL of the above solutions of different concentrations were added to cuvettes, and a thermocouple thermometer was inserted. The power was 1.5 W / cm 2 The liquid surface was irradiated with 808nm near-infrared light for 5 minutes, and the temperature was recorded every 10 seconds. A graph was drawn with time as the horizontal axis and temperature as the vertical axis to compare the photothermal effects of materials with different concentrations in vitro. Deionized water was used as the control group. The results are shown in Figure 6 A. Figure 6 As shown in D.

[0158] Secondly, the effect of laser power on the photothermal effect of the material was tested: First, 1 mL of the above micelle solution with a concentration of 75 μg / mL was added to the cuvette. Then, different powers (1, 1.5 and 2 W / cm 2 ), 808nm near-infrared light was irradiated on the liquid surface for 5 minutes. At room temperature, a thermocouple thermometer was inserted into the liquid surface and the temperature was recorded every 10 seconds. Pure water was used as the control group. The results are shown in Figure 6 As shown in B.

[0159] Finally, the photothermal stability of the material was tested: 1 mL of micelle solution with a concentration of 75 μg / mL was added to the cuvette and the power was 1.5 W / cm 2 , 808nm near-infrared light irradiation for 5 minutes, then stop irradiation to allow the temperature to drop to the starting temperature, and repeat this experimental operation 5 times. At room temperature, insert a thermocouple thermometer into the liquid surface and record the temperature every 10 seconds. The results are as follows Figure 6 As shown in C.

[0160] Figure 6 A is the time-temperature curve of the material under different concentration conditions. Figure 6It can be found in A that the higher the concentration, the more obvious the temperature rise. When the material concentration is 75μg / mL, the temperature rises by 58.5℃ within 5min.

[0161] Figure 6 B is the time-temperature curve of the material under different power conditions. Figure 6 It can be found in B that as the power increases, the temperature rises faster and the maximum temperature rises. 2 When the power is 2W / cm 2 When the temperature of the system increases from the initial 28.3℃ to 67.2℃.

[0162] Figure 6 C is the photothermal efficiency test diagram of the prepared micelles. Figure 6 It can be found in C that the nanomicelles have good photothermal stability, and five consecutive heating-cooling treatments do not affect their photothermal conversion efficiency.

[0163] Figure 6 D is the infrared thermal imaging image of the prepared micelles under 808nm laser irradiation. Figure 6 It can be found in D that within the 5-minute irradiation time, the temperature of the nanosystem can rise rapidly, and the degree of increase is positively correlated with the material concentration.

[0164] The implementation methods of the present invention are not limited to the above-mentioned embodiments, and any other changes, modifications, substitutions, combinations, and simplifications made without departing from the principles of the present invention shall be equivalent replacement methods and shall be included in the protection scope of the present invention.

Claims

1. A warm brain-targeted butylphthalide nano-drug delivery system, characterized in that: The drug delivery system is NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT, wherein NBP is butylphthalide, BPs is black phosphorus quantum dots, 6sPCL-bP(MEO2MA-co-OEGMA) is a thermosensitive amphiphilic nanopolymer, and CRT is a targeting molecule; the butylphthalide and black phosphorus quantum dots are co-encapsulated in the interior of 6sPCL-bP(MEO2MA-co-OEGMA), the CRT is connected to the hydrophilic surface of 6sPCL-bP(MEO2MA-co-OEGMA), and the CRT is a simulated cyclic peptide with the amino acid sequence shown below: CRTIGPSVC.

2. The butylphthalide nano drug delivery system according to claim 1, characterized in that: The CRT is connected to the hydrophilic surface of 6sPCL-bP (MEO2MA-co-OEGMA), and preferably the CRT is connected to the hydrophilic surface of 6sPCL-bP (MEO2MA-co-OEGMA) via a covalent bond.

3. The butylphthalide nano drug delivery system according to claim 1, characterized in that: The structure of 6sPCL-bP (MEO2MA-co-OEGMA) is shown in formula (II); R is C 10 H 16 O, structural formula is n is 8-16; p is 40-56; q is 1-5.

4. The butylphthalide nano drug delivery system according to claim 3, characterized in that: n is 10-14, preferably 12; p is 44-52, preferably 48; q is 2-4, preferably 3.

5. The butylphthalide nano drug delivery system according to claim 1, characterized in that: The LCST of the 6sPCL-bP (MEO2MA-co-OEGMA) is 40-50°C, preferably 42.3°C.

6. A method for preparing the warm brain-targeted butylphthalide nano-drug delivery system as claimed in claim 1, characterized in that: The steps include: S1, 6sPCL-bP(MEO2MA-co-OEGMA) was dissolved in solvent, water was added, and blank micelles were obtained after dialysis; S2, dissolving butylphthalide in THF to obtain a butylphthalide solution; mixing the blank micelle solution obtained in step S1 with the butylphthalide solution and black phosphorus quantum dots, adding water, and dialyzing to obtain a solution of NBP@BPs@6sPCL-bP (MEO2MA-co-OEGMA) loaded with black phosphorus quantum dots and butylphthalide loaded micelles; S3. Add EDC and NHS to the solution obtained in step S2 in sequence, add CRT polypeptide after the reaction, dialyze, and freeze-dry to obtain the drug-loaded micelles NBP@BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT.

7. The preparation method according to claim 6, characterized in that: In step S1, the solvent is preferably an organic solvent, more preferably THF; The weight ratio of EDC to NHS in step S3 is preferably 1:

1.

8. Use of the warm brain-targeted butylphthalide nano-drug delivery system according to any one of claims 1 to 5, characterized in that: Used for: (a) preparing a medicament for treating and / or preventing Alzheimer's disease; (b) Preparing a diagnostic and / or prognostic evaluation reagent for Alzheimer's disease.

9. A warm brain-targeted nano drug delivery system, the drug delivery system being BPs@6sPCL-bP(MEO2MA-co-OEGMA)-CRT, wherein BPs, 6sPCL-bP(MEO2MA-co-OEGMA), and CRT are as described in claim 1.

10. Use of the warm brain-targeted nano drug delivery system as claimed in claim 9 in the preparation of Alzheimer's disease diagnosis and / or prognosis assessment reagents.